Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

NCT02734004 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02734004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02734004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 17, 2016
Completion date
September 17, 2026
Enrollment
264 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

breast, gastric cancers, ovarian, sclc